Alicante, 09 of September 2026

COMMUNICATION – MARKET NOTICE - FACEPHI BIOMETRIA, S.A.

Dear Sirs,

Pursuant to Article 17 of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (Market Abuse Regulation), and section 4.5.1 of Euronext Growth Markets Rule Book Part I: Harmonized Rules, on ongoing obligations of companies listed on Euronext, (hereinafter "Facephi" or "the Company") hereby notifies the following:

At its meeting held on 7 September 2026, and following the resolution adopted by the Annual General Shareholders' Meeting on 30 June 2026 to increase the number of members of the Board of Directors, the Company's Board of Directors unanimously resolved to appoint Mr. Pablo Hurtado March and Mr. Stéphane Gard by co-option as members of the Board of Directors, both serving as independent directors.

These appointments shall remain in force until the first Shareholders' Meeting held following the resolution and shall be submitted for ratification in accordance with the applicable legal provisions.

Furthermore, the Board of Directors approved the reorganisation of its committees. The Audit and Control Committee shall be composed of Mr. Pablo Reig Boronat, independent director, serving as Chairman; Mr. Pablo Hurtado March, independent director, serving as a member; and Mr. Stéphane Gard, independent director, serving as a member.

In addition, the Appointments and Remuneration Committee shall be composed of Mr. Pablo Hurtado March, serving as Chairman, and Mr. Pablo Reig Boronat, Mr. Stéphane Gard, Mr. Juan Alfonso Ortiz Company and NICE & GREEN, S.A., represented by Mr. Manuel Lanfossi, serving as committee members.

We remain at your disposal for any clarification you might deem necessary.

Sincerely,

Javier Mira Miró
Chairman of the Board of Directors